NL301142I1 - - Google Patents
Info
- Publication number
- NL301142I1 NL301142I1 NL301142C NL301142C NL301142I1 NL 301142 I1 NL301142 I1 NL 301142I1 NL 301142 C NL301142 C NL 301142C NL 301142 C NL301142 C NL 301142C NL 301142 I1 NL301142 I1 NL 301142I1
- Authority
- NL
- Netherlands
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461949808P | 2014-03-07 | 2014-03-07 | |
| US201461981515P | 2014-04-18 | 2014-04-18 | |
| PCT/US2015/019535 WO2015134998A1 (en) | 2014-03-07 | 2015-03-09 | Human plasma kallikrein inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL301142I1 true NL301142I1 (enExample) | 2021-11-03 |
| NL301142I2 NL301142I2 (nl) | 2021-12-09 |
Family
ID=54055948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301142C NL301142I2 (nl) | 2014-03-07 | 2021-11-01 | Berotralstat en farmaceutisch aanvaardbare zouten daarvan |
Country Status (33)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6479763B2 (ja) | 2013-03-25 | 2019-03-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン |
| GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| ES2784841T3 (es) | 2014-01-31 | 2020-10-01 | Bristol Myers Squibb Co | Macrociclos con grupos aromáticos P2' como inhibidores del factor XIa |
| NO2760821T3 (enExample) | 2014-01-31 | 2018-03-10 | ||
| CA3164693A1 (en) | 2014-03-07 | 2015-09-11 | Biocryst Pharmaceuticals, Inc. | Human plasma kallikrein inhibitors |
| JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｆｘｉａ阻害剤であるジアミドマクロ環 |
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| SG10202003705WA (en) | 2015-10-01 | 2020-06-29 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
| MD3464271T2 (ro) | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Derivați de pirazol în calitate de inhibitori ai kaliсreinei plasmatice |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| HUE057912T2 (hu) | 2017-11-29 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma kallikrein inhibitort tartalmazó dózisformák |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| UY38438A (es) * | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| EP3953395A4 (en) * | 2019-04-08 | 2023-01-18 | Biocryst Pharmaceuticals, Inc. | PLASMACALLICREIN INHIBITORS AND METHODS OF USE THEM IN EYE DISEASES |
| WO2021025969A1 (en) | 2019-08-02 | 2021-02-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of berotralstat |
| UA130182C2 (uk) * | 2019-08-06 | 2025-12-10 | Байокріст Фармасьютикалз, Інк. | Синтез інгібітора плазмового калікреїну в технологічному обсязі |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| EP4017850A1 (en) * | 2019-08-21 | 2022-06-29 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| JP2023515073A (ja) | 2020-02-20 | 2023-04-12 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ媒介障害の処置用のヘテロアリール化合物 |
| EP4116299A4 (en) | 2020-03-04 | 2024-03-27 | Medshine Discovery Inc. | HETEROCYCLIC COMPOUND |
| JP7776453B2 (ja) * | 2020-06-16 | 2025-11-26 | メルク・シャープ・アンド・ドーム・エルエルシー | 血漿カリクレイン阻害剤 |
| KR20230038526A (ko) * | 2020-07-10 | 2023-03-20 | 머크 샤프 앤드 돔 엘엘씨 | 혈장 칼리크레인 억제제 |
| WO2022060842A1 (en) * | 2020-09-15 | 2022-03-24 | The Trustees Of Columbia University In The City Of New York | Systems and methods for predicting graft dysfunction with exosome proteins |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| CN116375648A (zh) * | 2023-03-22 | 2023-07-04 | 苏州农平科技发展有限公司 | 贝罗司他中间体的制备方法 |
| WO2025122555A1 (en) * | 2023-12-05 | 2025-06-12 | Valo Health, Inc. | S1p 1 receptor agonists and uses thereof |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| DE3633840A1 (de) | 1986-10-04 | 1988-04-14 | Hoechst Ag | Phenylpyrazolcarbonsaeurederivate, ihre herstellung und verwendung als pflanzenwachstumsregulatoren und safener |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic, Inc., Minneapolis, Minn. | Intraluminale prothese mit wirkstoffeluierung. |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| NZ336162A (en) * | 1996-12-23 | 2000-09-29 | Du Pont Pharm Co | pyrrole, tetrazole or pyrazole derivatives useful as factor Xa inhibitors |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| HRP980334A2 (en) * | 1997-06-19 | 1999-04-30 | Mimi Lifen Quan | INHIBITORS OF FACTOR Xa WITH A NEUTRAL P1 SPECIFICITY GROUP |
| ZA985247B (en) * | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| EP1042299A1 (en) * | 1997-12-22 | 2000-10-11 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| US6271237B1 (en) * | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
| KR100659007B1 (ko) * | 1999-02-10 | 2007-02-28 | 미츠비시 웰파마 가부시키가이샤 | 아미드 화합물 및 그 의약으로서의 용도 |
| AU4327600A (en) | 1999-04-02 | 2000-10-23 | Du Pont Pharmaceuticals Company | Aryl sulfonyls as factor xa inhibitors |
| US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6329527B1 (en) | 1999-10-21 | 2001-12-11 | Bristol-Myers Squibb Pharma Company | Synthesis of 1,3,5-trisubstituted pyrazoles |
| WO2002000651A2 (en) * | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| PL201530B1 (pl) | 2000-06-27 | 2009-04-30 | L V A T Lab Sa | Karbaminiany pochodne aryloalkiloamin i zastosowanie karbaminianów pochodnych aryloalkiloamin |
| EP1366045A2 (en) | 2000-09-22 | 2003-12-03 | Bristol-Myers Squibb Pharma Company | Efficient process for the preparation of a factor xa inhibitor |
| MXPA03009311A (es) | 2001-04-12 | 2004-02-12 | Hoffmann La Roche | Derivados de dihidro-benzo[b][1,4]diazepin-2-ona como antagonistas ii del receptor metabotropico de glutamato (mglur2). |
| MY142967A (en) | 2001-08-13 | 2011-01-31 | Du Pont | Method for controlling particular insect pests by applying anthranilamide compounds |
| AU2002319814A1 (en) * | 2001-08-13 | 2003-03-03 | E.I. Du Pont De Nemours And Company | Substituted 1h-dihydropyrazoles, their preparation and use |
| TW200724033A (en) | 2001-09-21 | 2007-07-01 | Du Pont | Anthranilamide arthropodicide treatment |
| JP2005504084A (ja) * | 2001-09-21 | 2005-02-10 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 殺虫性ジアミド |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
| TW200303309A (en) | 2001-12-04 | 2003-09-01 | Bristol Myers Squibb Co | Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors |
| EP1513817A1 (en) | 2002-05-24 | 2005-03-16 | Takeda Pharmaceutical Company Limited | 1, 2-azole derivatives with hypoglycemic and hypolipidemic activity |
| MXPA04012214A (es) * | 2002-06-13 | 2005-02-25 | Du Pont | Insecticidas de pirazolcarboxamida. |
| DE10229070A1 (de) * | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| BRPI0407088A (pt) | 2003-01-28 | 2006-01-24 | Aventis Pharma Sa | Produtos n-aril-heteroaromáticos, composições contendo os mesmos e seu uso |
| AU2004270733B2 (en) | 2003-09-11 | 2011-05-19 | Itherx Pharma, Inc. | Cytokine inhibitors |
| WO2005094805A1 (ja) * | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| JP2007532661A (ja) | 2004-04-13 | 2007-11-15 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | アントラニルアミド殺虫剤 |
| WO2005113522A1 (en) | 2004-05-07 | 2005-12-01 | Janssen Pharmaceutica, N.V. | Azole carboxamide inhibitors of bacterial type iii protein secretion systems |
| US20060069270A1 (en) | 2004-09-27 | 2006-03-30 | Rafael Shapiro | Process for the preparation of 1,3,5-trisubstituted pyrazoles via [3+2] cycloaddition |
| US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
| ES2413442T3 (es) | 2004-11-18 | 2013-07-16 | E. I. Du Pont De Nemours And Company | Insecticidas de antranilamida |
| EP1820795A4 (en) * | 2004-12-07 | 2010-10-20 | Toyama Chemical Co Ltd | NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| GB0516703D0 (en) | 2005-08-15 | 2005-09-21 | Syngenta Participations Ag | Novel insecticides |
| JP5186751B2 (ja) * | 2005-10-14 | 2013-04-24 | 住友化学株式会社 | ヒドラジド化合物およびその有害生物防除用途 |
| BRPI0617221B1 (pt) | 2005-10-14 | 2016-07-12 | Sumitomo Chemical Co | composto de hidrazida, seu uso, pesticida e método de controlar uma peste |
| PE20070795A1 (es) | 2005-10-28 | 2007-08-24 | Lilly Co Eli | Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa |
| ATE525072T1 (de) | 2006-02-09 | 2011-10-15 | Athersys Inc | Pyrazole zur behandlung von adipositas und anderen zns-erkrankungen |
| NZ573573A (en) * | 2006-05-16 | 2011-10-28 | Boehringer Ingelheim Int | Substituted prolinamides, production thereof and their use as drugs |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| CN101495468A (zh) * | 2006-07-31 | 2009-07-29 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂 |
| US7625944B2 (en) | 2006-07-31 | 2009-12-01 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| JP2010509349A (ja) | 2006-11-03 | 2010-03-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| AU2007333194A1 (en) * | 2006-12-08 | 2008-06-19 | Exelixis, Inc. | LXR and FXR modulators |
| EP2137158A4 (en) | 2007-02-28 | 2012-04-18 | Methylgene Inc | LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS) |
| CN101298451B (zh) | 2007-04-30 | 2013-01-30 | 中国中化股份有限公司 | 苯甲酰胺类化合物及其应用 |
| WO2008134969A1 (fr) | 2007-04-30 | 2008-11-13 | Sinochem Corporation | Composés benzamides et leurs applications |
| CA2747035C (en) * | 2008-12-18 | 2017-01-24 | Bayer Cropscience Ag | Tetrazole substituted anthranilic acid amides as pesticides |
| CN102365278B (zh) | 2009-03-26 | 2015-05-06 | 先正达参股股份有限公司 | 杀虫化合物 |
| US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
| KR20120120237A (ko) | 2009-12-18 | 2012-11-01 | 액티브사이트 파마슈티칼즈, 인크. | 혈장 칼리크레인 억제제의 전구약물 |
| US8815896B2 (en) | 2010-02-01 | 2014-08-26 | The Institute Of Cancer Research: Royal Cancer Hospital | 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| JPWO2011118818A1 (ja) | 2010-03-26 | 2013-07-04 | 味の素株式会社 | アミジノアニリン誘導体 |
| CN102285963B (zh) | 2010-06-21 | 2014-04-09 | 中国中化股份有限公司 | 3-甲氧基吡唑酰胺类化合物及其应用 |
| MX2013002011A (es) | 2010-08-20 | 2013-03-25 | Gruenenthal Gmbh | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor vainiloide. |
| BR112013010768A2 (pt) | 2010-11-10 | 2016-07-12 | Gruenenthal Gmbh | derivados de ureia e carboxamida substituídos por heteroaromáticos como ligantes dos receptores vaniloides |
| US9284298B2 (en) | 2011-04-11 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| US8691861B2 (en) * | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| WO2013036232A2 (en) | 2011-09-08 | 2013-03-14 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| AR088799A1 (es) | 2011-11-09 | 2014-07-10 | Gruenenthal Gmbh | Derivados de carboxamida y urea a base de pirazolilos sustituidos que contienen una porcion fenilo sustituida con un grupo que contiene so₂ como ligandos del receptor de vanilloide |
| CN103467380B (zh) | 2013-09-29 | 2015-06-24 | 南开大学 | 一类取代苯基吡唑酰胺衍生物及其制备方法和应用 |
| CA3164693A1 (en) | 2014-03-07 | 2015-09-11 | Biocryst Pharmaceuticals, Inc. | Human plasma kallikrein inhibitors |
| UY38438A (es) | 2018-11-02 | 2020-05-29 | Biocryst Pharm Inc | Sales cristalinas de un inhibidor de calicreína plasmática |
| UA130182C2 (uk) | 2019-08-06 | 2025-12-10 | Байокріст Фармасьютикалз, Інк. | Синтез інгібітора плазмового калікреїну в технологічному обсязі |
-
2015
- 2015-03-09 CA CA3164693A patent/CA3164693A1/en active Pending
- 2015-03-09 RS RS20221083A patent/RS63763B1/sr unknown
- 2015-03-09 US US15/123,059 patent/US10125102B2/en active Active
- 2015-03-09 PL PL20191747.3T patent/PL3828173T3/pl unknown
- 2015-03-09 HU HUE20191747A patent/HUE060660T2/hu unknown
- 2015-03-09 EP EP15759254.4A patent/EP3113772B8/en active Active
- 2015-03-09 JP JP2016555752A patent/JP6574435B2/ja active Active
- 2015-03-09 SM SM20210031T patent/SMT202100031T1/it unknown
- 2015-03-09 SM SM20230002T patent/SMT202300002T1/it unknown
- 2015-03-09 EP EP20191747.3A patent/EP3828173B1/en active Active
- 2015-03-09 HU HUE15759254A patent/HUE052668T2/hu unknown
- 2015-03-09 IL IL280785A patent/IL280785B2/en unknown
- 2015-03-09 SG SG10202001795XA patent/SG10202001795XA/en unknown
- 2015-03-09 MX MX2020013059A patent/MX2020013059A/es unknown
- 2015-03-09 MA MA53399A patent/MA53399B1/fr unknown
- 2015-03-09 ES ES15759254T patent/ES2836373T3/es active Active
- 2015-03-09 AU AU2015226855A patent/AU2015226855C1/en active Active
- 2015-03-09 BR BR112016020199A patent/BR112016020199A8/pt not_active Application Discontinuation
- 2015-03-09 DK DK15759254.4T patent/DK3113772T3/da active
- 2015-03-09 PT PT201917473T patent/PT3828173T/pt unknown
- 2015-03-09 EP EP22191079.7A patent/EP4180424B1/en active Active
- 2015-03-09 SI SI201531442T patent/SI3113772T1/sl unknown
- 2015-03-09 CN CN201580022369.5A patent/CN106257976B/zh active Active
- 2015-03-09 ES ES22191079T patent/ES3039514T3/es active Active
- 2015-03-09 HR HRP20201916TT patent/HRP20201916T1/hr unknown
- 2015-03-09 EA EA201691803A patent/EA036251B1/ru unknown
- 2015-03-09 NZ NZ762034A patent/NZ762034A/en unknown
- 2015-03-09 PL PL15759254T patent/PL3113772T3/pl unknown
- 2015-03-09 MX MX2016011468A patent/MX377845B/es unknown
- 2015-03-09 RS RS20201483A patent/RS61159B1/sr unknown
- 2015-03-09 LT LTEP15759254.4T patent/LT3113772T/lt unknown
- 2015-03-09 KR KR1020167026786A patent/KR102510427B1/ko active Active
- 2015-03-09 PH PH1/2016/501750A patent/PH12016501750B1/en unknown
- 2015-03-09 SG SG11201607267SA patent/SG11201607267SA/en unknown
- 2015-03-09 ES ES20191747T patent/ES2932406T3/es active Active
- 2015-03-09 KR KR1020237008388A patent/KR102736869B1/ko active Active
- 2015-03-09 HR HRP20221373TT patent/HRP20221373T1/hr unknown
- 2015-03-09 WO PCT/US2015/019535 patent/WO2015134998A1/en not_active Ceased
- 2015-03-09 LT LTEP20191747.3T patent/LT3828173T/lt unknown
- 2015-03-09 NZ NZ724250A patent/NZ724250A/en unknown
- 2015-03-09 PT PT157592544T patent/PT3113772T/pt unknown
- 2015-03-09 DK DK20191747.3T patent/DK3828173T3/da active
- 2015-03-09 EP EP25184854.5A patent/EP4663636A2/en active Pending
- 2015-03-09 CA CA2941380A patent/CA2941380C/en active Active
- 2015-03-09 MY MYPI2016001634A patent/MY199131A/en unknown
- 2015-03-09 CN CN202110045874.9A patent/CN113307772B/zh active Active
-
2016
- 2016-08-28 IL IL247518A patent/IL247518B/en active IP Right Grant
- 2016-09-13 ZA ZA2016/06320A patent/ZA201606320B/en unknown
-
2018
- 2018-05-11 US US15/977,129 patent/US10329260B2/en active Active
- 2018-06-15 US US16/009,943 patent/US10633345B2/en active Active
-
2019
- 2019-05-01 US US16/400,798 patent/US10689346B2/en active Active
- 2019-08-16 JP JP2019149385A patent/JP6915003B2/ja active Active
-
2020
- 2020-03-24 US US16/828,763 patent/US11203574B2/en active Active
- 2020-03-24 US US16/828,755 patent/US11192861B2/en active Active
- 2020-04-10 US US16/845,833 patent/US11230530B2/en active Active
- 2020-10-27 AU AU2020260400A patent/AU2020260400B2/en active Active
- 2020-12-08 CY CY20201101164T patent/CY1123810T1/el unknown
-
2021
- 2021-07-14 JP JP2021116716A patent/JP2021169499A/ja active Pending
- 2021-10-08 CY CY2021029C patent/CY2021029I2/el unknown
- 2021-10-14 LU LU00233C patent/LUC00233I2/fr unknown
- 2021-10-25 FR FR21C1048C patent/FR21C1048I2/fr active Active
- 2021-10-25 HU HUS2100045C patent/HUS2100045I1/hu unknown
- 2021-10-26 LT LTPA2021524C patent/LTC3113772I2/lt unknown
- 2021-11-01 NL NL301142C patent/NL301142I2/nl unknown
- 2021-11-09 US US17/522,065 patent/US11685721B2/en active Active
- 2021-11-15 US US17/526,377 patent/US11708332B2/en active Active
- 2021-12-07 US US17/543,929 patent/US11708333B2/en active Active
-
2022
- 2022-10-25 AU AU2022259742A patent/AU2022259742B2/en active Active
- 2022-11-07 NO NO2022046C patent/NO2022046I1/no unknown
-
2023
- 2023-04-18 US US18/136,016 patent/US12162838B2/en active Active
- 2023-04-18 US US18/136,025 patent/US12116346B2/en active Active
- 2023-11-06 JP JP2023189564A patent/JP2023181543A/ja active Pending
-
2024
- 2024-09-24 US US18/894,797 patent/US20250257040A1/en active Pending
- 2024-10-11 US US18/913,643 patent/US20250270171A1/en active Pending